Summary of Altimmune Conference Call Company Overview - **Company**: Altimmune - **Event**: Leerink Partners Global Healthcare Conference - **Key Participants**: CEO Jerry Durso, CMO Christophe Arbet-Engels, CFO Greg Weaver Industry Focus - **Primary Focus**: MASH (Metabolic Associated Steatotic Liver Disease) - **Clinical Trials**: Phase 2 and Phase 3 trials for pemvidutide, a treatment for MASH and other liver-related diseases Key Points and Arguments Clinical Data and Regulatory Progress - **2025 Highlights**: Significant clinical data expected, including two readouts from the Phase 2 MASH trial in 2025, with 24-week and 48-week data showing promising results for pemvidutide [6][18] - **Regulatory Feedback**: Received breakthrough therapy designation from the FDA, indicating strong alignment on Phase 3 trial design [6][34] - **Phase 3 Trial**: Focus on a 52-week endpoint to assess antifibrotic effects, with a simple titration scheme for dosing to improve tolerability [20][27] Pemvidutide Differentiation - **Mechanism of Action**: Pemvidutide combines glucagon and GLP-1 in a 1:1 ratio, which is believed to provide a balanced therapeutic effect, unlike competitors like survodutide, which has a 7:1 ratio favoring GLP-1 [10][12] - **Tolerability**: Pemvidutide shows lower discontinuation rates compared to other treatments, with less than placebo rates of discontinuation [13][33] - **Efficacy**: Strong indications of antifibrotic effects observed in non-invasive tests, with confidence in achieving significant results in the upcoming Phase 3 trial [18][19] Market Position and Strategy - **Patient Segmentation**: Physicians are expected to segment patients based on tolerability and efficacy, with pemvidutide positioned as a favorable option for patients who struggle with other incretin therapies [63][64] - **Combination Therapy Potential**: Pemvidutide may serve as a complementary agent in combination therapies, enhancing efficacy without increasing side effects [58][59] Upcoming Trials and Endpoints - **Alcohol Use Disorder (AUD) and Alcohol-Related Liver Disease (ALD)**: Two unique Phase 2 programs are underway, targeting large unmet needs in these areas [67][68] - **Endpoints for AUD**: Focus on reducing heavy drinking days, with a target of a 1-day reduction in average heavy drinking days as a meaningful clinical outcome [75][77] Regulatory Considerations - **FDA Engagement**: Ongoing discussions with the FDA regarding the use of non-invasive tests (NITs) for regulatory approval, with potential for evolving acceptance during the trial [42][46] - **Global Alignment**: Efforts to align with European regulatory bodies (EMA, MHRA) to ensure a cohesive global strategy for pemvidutide [51] Additional Important Insights - **Long-term Market Outlook**: The MASH market is expected to evolve similarly to the diabetes market, with multiple mechanisms and treatment options becoming available [65] - **Focus on F4 Population**: While the primary focus remains on F2 and F3 populations, there is potential for future exploration in the F4 compensated cirrhotic population [54] This summary encapsulates the critical insights and strategic directions discussed during the Altimmune conference call, highlighting the company's focus on advancing pemvidutide as a leading treatment option in the MASH and liver disease landscape.